Real-World, Long-Term Data Collection to Gain Clinical Insights Into Roche Ophthalmology Products (VOYAGER STUDY)
Real-World, Long-Term Data Collection to Gain Clinical Insights Into Roche Ophthalmology Products (VOYAGER STUDY)
The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products in approved retinal indications (Faricimab for neovascular age-related macular degeneration [nAMD], diabetic macular edema [DME], and retinal vein occlusion; Port Delivery System with Ranibizumab for nAMD) in routine clinical practice. This study will not provide or make recommendations on use of any products including Roche products; treatment decisions will be determined by the treating physician and must be made independently to the decision to participate in this study. Participation in this study will not change or influence a patient's standard of care in any way.
Inclusion Criteria:
1. Have provided informed consent, as required per local regulations 2.a) Adult patient, as defined by local regulations and local product label, who is newly initiating treatment (or initiated treatment in the previous visit) with a specified approved Roche ophthalmology product in retinal indication of interest for this study in at least one eye, according to the investigator's discretion in routine clinical practice; OR 2.b) Adult patient, as defined by local regulations and local product label, who is continuing treatment with any specified approved Roche ophthalmology product in retinal indication of interest for this study in at least one eye after initiating that treatment in a Roche interventional trial.
Exclusion Criteria:
1. Concomitant participation of the patient in an investigational ophthalmology clinical trial that includes receipt of any investigational drug or procedure within the last 28 days prior to enrollment (this restriction does not apply to patients who are rolling over from Roche interventional studies and continuing treatment with any specified approved Roche ophthalmology product in retinal indication of interest for this study)
Ciudad Autonoma de Buenos Aires, Buenos Aires C1056, Argentina
Ciudad Autonoma Buenos Aires, C1116ABA, Argentina
Sofia, 1784, Bulgaria
Trier, Bavaria 86438, Germany
Dessau, Saxony-Anhalt 06847, Germany
Udine, Friuli Venezia Giulia 33100, Italy
Milan, Lombardy 20142, Italy
Milan, Lombardy, Italy
Acquaviva Delle Fonti, Piedmont 70021, Italy
Sassuolo, Sardinia 41049, Italy
Catania, Sicily 95123, Italy
Nagakute-shi, Aichi-ken 480-1195, Japan
Sakura-shi, Chiba 285-8741, Japan
Shimotsuke-shi, Tochigi 329-0498, Japan
Chiyoda-ku, Tokyo-To 101-8309, Japan
Shinjuku-ku, Tokyo-To 160-0023, Japan
Shinjuku-ku, Tokyo-To 160-8582, Japan
Chuo-shi, 409-3898, Japan
Hokkaido, 060-8604, Japan
Meguro-ku, 152-8902, Japan
Takatsuki-shi, 569-8686, Japan
Yoshida-gun, 910-1193, Japan
Muang, Changwat Khon Kaen 40002, Thailand
Gorleston-on-Sea, Norfolk NR31 6LA, United Kingdom